Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...
Quidel Corporation (Nasdaq: QDEL) is a Californ...
MedChain's mission is to use blockchain technology to establish a better, more sec...
MedChain's mission is to use blockchain technol...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.